Results 201 to 210 of about 94,825 (337)

Cellular Mechanism and Key Insights in Allergen Immunotherapy for Allergic Rhinitis

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Allergic rhinitis (AR) arises from immune responses mediated by immunoglobulin E (IgE) to inhaled allergens, representing one of the most prevalent chronic conditions worldwide. Although AR may not be a serious ailment, it holds clinical relevance as it underpins numerous complications, serves as a major risk factor for suboptimal asthma ...
Zhe Wang   +3 more
wiley   +1 more source

Pteryxin enhances human NK-cell cytotoxicity by upregulating NKp30, NKp46, and 2B4 via ERK/AKT signaling. [PDF]

open access: yesFront Pharmacol
Park ES   +7 more
europepmc   +1 more source

Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T‐Cell Enhancement in Immunocompetent HLA‐Transgenic Mice

open access: yesAllergy, EarlyView.
Upregulated HLA‐B*57:01 expression in Tg/KO mice amplifies abacavir‐specific CD8+ T‐cell activation, driven by enhanced antigen presentation. Abacavir treatment induces robust pDC expansion and IFN‐α production, which selectively suppresses memory Treg populations.
SuJin Hwang   +8 more
wiley   +1 more source

Infection control in the brain and the eye

open access: yesActa Ophthalmologica, EarlyView.
Abstract The Central Nervous System (CNS), comprising the brain and the eye, is considered to have a ‘privileged’ mechanism for dealing with immunological challenge (immune privilege, IP). CNS IP has been revealed through experiments using foreign protein antigens and cell and tissue alloantigens (grafts), but evidence for a role for IP in modulating ...
John V. Forrester   +2 more
wiley   +1 more source

Induction of IL‐9‐producing CD8+ T cells by ascochlorin derivatives

open access: yesBritish Journal of Pharmacology, EarlyView.
A newly synthesised ascochlorin derivative, N184, induces small amounts of IL‐9‐producing CD8+ T cells. N184 improved the survival of CD8+ T cells and enhanced their antitumour activity, partially in an IL‐9‐dependent manner. The antitumour effect was completely dependent on IFNγ secretion rather than the cytotoxic activity of CD8+ T cells.
Natsumi Imano   +5 more
wiley   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

open access: yesBritish Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun   +2 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy